NCT03445897View on ClinicalTrials.gov

Miltefosine Plus IL Pentamidine for Bolivian CL

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

January 31, 2018

Study Completion Date

February 21, 2018

Conditions
Leishmaniasis, Cutaneous
Interventions
DRUG

miltefosine plus intralesional pentamidine

miltefosine (150 mg/day for 28 days) plus intralesional pentamidine (120 ug/mm2 lesion area on days 1, 3, and 5).

All Listed Sponsors
lead

Jonathan Berman

OTHER

NCT03445897 - Miltefosine Plus IL Pentamidine for Bolivian CL | Biotech Hunter | Biotech Hunter